Dimension Capital announced its third fund of $800 million, a 60% increase over its previous $500 million vehicle, underscoring rising investor appetite for deep-tech ventures at the intersection of biotechnology and computation. The New York firm, founded by Zavian Dar, Adam Goulburn, and Nan Li, targets early-stage companies that merge software, AI, and biology to tackle complex scientific problems. Notable portfolio moves include leading a $30 million seed round for Chai Discovery in 2024, with the company later securing about $400 million at a $3.8 billion valuation, and backing anti-aging startup New Limit through a January 2025 Series A that progressed to a $3.1 billion valuation by its Series C. Dimension also has exposure to other AI and inference players like Modal Labs and Anthropic, and holds stakes in Anthropic after Anthropic acquired Coefficient Bio for roughly $400 million. The fundraise and portfolio activity reflect a broader trend of accelerating investments in platform-scale biology and AI-driven drug discovery, with multiple portfolio companies delivering rapid progress and high valuations.